From London: Yellowstone Biosciences is leveraging an Oxford AML patient biobank to develop an HLA Class II platform of T-cell engagers
From Syncona's Capital Markets Day, CEO Jim MacDonald describes the learnings Yellowstone has gained from looking at cured AML patients from the Oxford biobank and how it is translating that into new medicines.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.